
Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
6 Famous Cell phone Brands All over The Planet - 2
23 Most Amusing Messages At any point Sent Among Youngsters and Their Folks - 3
A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30 - 4
Russian drone slams into block of flats in deadly wave of strikes across Kyiv - 5
Black Friday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
Israel explores creation of int'l force with Greece, Cyprus to deter Turkey
Well known SUVs With Low Energy Utilization In 2024 vote
Sunken warship found off Danish coast after 225 years in ‘remarkable’ discovery
Remains of banker missing since 1999 found on California beach by family looking for seashells
The Solution to Innovative Peculiarity: Analyzing the Fate of Mankind
'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
A throat bone settles it - Nanotyrannus was not a juvenile T. rex
Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness
Pick the Ideal Family Feline Variety for Your Home













